1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Intermittent Claudication - Pipeline Review, H1 2016

Intermittent Claudication - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 51 pages

Intermittent Claudication - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Intermittent Claudication - Pipeline Review, H1 2016’, provides an overview of the Intermittent Claudication pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Intermittent Claudication
- The report reviews pipeline therapeutics for Intermittent Claudication by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Intermittent Claudication therapeutics and enlists all their major and minor projects
- The report assesses Intermittent Claudication therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Intermittent Claudication

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Intermittent Claudication
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Intermittent Claudication pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Intermittent Claudication - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Intermittent Claudication Overview 6
Therapeutics Development 7
Pipeline Products for Intermittent Claudication - Overview 7
Intermittent Claudication - Therapeutics under Development by Companies 8
Intermittent Claudication - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Intermittent Claudication - Products under Development by Companies 11
Intermittent Claudication - Companies Involved in Therapeutics Development 12
ID Pharma Co., Ltd. 12
Kowa Company, Ltd. 13
Nuo Therapeutics, Inc. 14
Pluristem Therapeutics Inc. 15
Intermittent Claudication - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
ALD-301 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
DVC-10101 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
K-134 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
LT-0101 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
PLX-PAD - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Intermittent Claudication - Recent Pipeline Updates 35
Intermittent Claudication - Dormant Projects 43
Intermittent Claudication - Discontinued Products 44
Intermittent Claudication - Product Development Milestones 45
Featured News and Press Releases 45
Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications 45
Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea 45
Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel 45
Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study 46
Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells 46
Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study 47
Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany 47
Aug 23, 2012: Pluristem Commences Phase II Clinical Trial for Intermittent Claudication Using PLX Cells 47
Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research 48
Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study 48
Appendix 50
Methodology 50
Coverage 50
Secondary Research 50
Primary Research 50
Expert Panel Validation 50
Contact Us 50
Disclaimer 51

List of Tables
Number of Products under Development for Intermittent Claudication, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Intermittent Claudication - Pipeline by ID Pharma Co., Ltd., H1 2016 12
Intermittent Claudication - Pipeline by Kowa Company, Ltd., H1 2016 13
Intermittent Claudication - Pipeline by Nuo Therapeutics, Inc., H1 2016 14
Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc., H1 2016 15
Assessment by Monotherapy Products, H1 2016 16
Number of Products by Stage and Target, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Intermittent Claudication Therapeutics - Recent Pipeline Updates, H1 2016 35
Intermittent Claudication - Dormant Projects, H1 2016 43
Intermittent Claudication - Discontinued Products, H1 2016 44

List of Figures
Number of Products under Development for Intermittent Claudication, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Assessment by Monotherapy Products, H1 2016 16
Number of Products by Targets, H1 2016 17
Number of Products by Stage and Targets, H1 2016 17
Number of Products by Mechanism of Actions, H1 2016 19
Number of Products by Stage and Mechanism of Actions, H1 2016 19
Number of Products by Routes of Administration, H1 2016 21
Number of Products by Stage and Routes of Administration, H1 2016 21
Number of Products by Molecule Types, H1 2016 23
Number of Products by Stage and Molecule Types, H1 2016 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.